- Bannen, Lynne Canne; Chan, Diva Sze-ming; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Jammalamadaka, Vasu; Khoury, Richard George; Leahy, James William; Mac, Morrison B.; et al, C-MET Modulators And Methods Of Use, Exelixis, Inc., United States, WO2005030140A2, April 7. 2005 (https://patents.google.com/patent/WO2005030140A2/en)
- Wu, Chunyong; Xu, Xue; Feng, Chao; Shi, Yuanyuan; Liu, Wenyuan; Zhu, Xiaoyun; Zhang, Junying, Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, Volume: 98, Pages: 356-363, 2014
Frequently Asked Questions
Cabozantinib impurities are any substances or contaminants present in Cabozantinib drug products.
Cabozantinib impurities can have unknown pharmacological effects and can potentially harm patients, so it's essential to identify and control them.
Cabozantinib impurities cannot be removed from the drug product, but their levels can be minimized through effective manufacturing processes and monitoring.
Cabozantinib impurities are monitored throughout the manufacturing process and over the shelf life of the drug product to ensure that their levels remain within acceptable limits.
Cabozantinib impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.